News

IntegraGen Sees 2024 Revenue Drop but Strong Growth Ahead

IntegraGen Sees 2024 Revenue Drop but Strong Growth Ahead

IntegraGen Reports 2024 Results with Insights Into Future Growth

IntegraGen, a company renowned for its focus on cancer and rare genetic disease genomics, has shared its financial performance for the year 2024. Despite concerns over a revenue decline, insights reveal areas of strength and potential for future development.

Revenue Overview for 2024

The company's unaudited revenue for 2024 reached €8.5 million, representing a 27% decrease compared to 2023. This downturn primarily stems from the cessation of SeqOIA platform services earlier in the year, which was a strategic move under a contract awarded to IntegraGen back in 2018. Revenue from this platform fell dramatically from €4.3 million in 2023 to merely €858,000 in 2024.

Interestingly, when excluding the SeqOIA impact, revenue showed a positive trend, increasing by 5%. This indicates that the underlying business remains robust, particularly in its genomic services, which recorded an 8% growth in Évry.

Non-Recurring Revenues and Cash Position

In addition to its core revenues, IntegraGen recognized non-recurring revenues, including hardware and software sales related to SeqOIA, amounting to €399,000. Overall, the total income, inclusive of these items, reached €8.9 million.

The company ended the year with a cash position of €1.9 million. This represents a significant dip, dropping by €1 million from the close of 2023. The cash variation is chiefly attributable to reduced revenue, changes in customer payment habits, and loan repayments. Notably, €642,000 of this cash position consists of an outstanding balance of a State Guaranteed Loan obtained amid the pandemic.

Future Growth Prospects

Despite the challenges faced in 2024, the outlook for the future appears promising. IntegraGen's order book has strengthened, fueled by ongoing sales momentum and multi-year contracts that provide stability and growth opportunities. The January award of CLIA certification broadens the company's horizons, allowing it to conduct studies for pharmaceutical firms developing innovative drugs.

A highlight of this pursuit is a newly signed contract valued at €2.4 million, which pertains to a prospective Phase II clinical trial. This contract not only validates IntegraGen's expertise but also underscores its potential in providing valuable services to the pharmaceutical sector.

Leadership Commentary

Bernard Courtieu, the Chief Executive Officer of IntegraGen, expressed optimism regarding the company's future. He remarked, "Excluding SeqOIA-related activities, our sales in 2024 still grew, affirming the resilience of our business model. We are committed to attracting a broader client base, including industrial pharmaceutical companies, to enhance our growth trajectory and profitability. While we manage through 2024's restructuring phase, our sights are set on achieving profitable growth moving forward."

About IntegraGen

Founded as part of the OncoDNA group, IntegraGen specializes in genomic analysis focused on both cancer and rare genetic diseases. The company prides itself on its cutting-edge DNA sequencing services and expertise in genomic data interpretation software. With a robust team and capabilities, IntegraGen operates one of France's largest NGS laboratories, catering to prestigious research institutes.

IntegraGen employs approximately 42 people and, despite the recent revenue challenges, generated €8.5 million in turnover for 2024. As a publicly listed entity on Euronext Growth in Paris, the company is positioned for ongoing collaborations and innovations within the realm of precision medicine.

Frequently Asked Questions

What were IntegraGen's revenues in 2024?

IntegraGen reported unaudited revenues of €8.5 million for the year 2024, reflecting a 27% decrease compared to the previous year.

What caused the decline in revenues?

The decline was significantly influenced by the cessation of the SeqOIA platform services, which accounted for a substantial portion of previous years' earnings.

How did IntegraGen's non-recurring revenues impact its financials?

The non-recurring revenues from hardware and software sales added €399,000, bringing total income to €8.9 million for 2024.

What is IntegraGen's cash position at the end of 2024?

The company ended 2024 with a cash position of €1.9 million, a decrease from 2023, due to lost revenues and loan repayments.

What is the future outlook for IntegraGen?

IntegraGen has a promising future, bolstered by a strengthened order book, CLIA certification, and a significant contract signed for a Phase II clinical trial set to enhance growth prospects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 179

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 106

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 137

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 74

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 106

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 150

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 95

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
IM Cannabis's Third Quarter Financial Jolt

Updated Category News Views 143

IM Cannabis Takes a Hit, But Seeks New Angles Diving into IM Cannabis's (NASDAQ: IMCC) latest financial splash is like reading a weathered old map of the stock market. The third quarter of 2026 wasn't kind to this little cannabis outfit. Revenues have nosedived to C$1.65 million from last year's C$5.08 million. It's not just the typical bad quarter blues; it's a solid...

Continue Reading

Top 5 Most Recently Viewed Articles

Berry Global Plans Senior Secured Notes Offering Ahead of Merger

Updated Category News Views 126

Berry Global’s Strategic Offering of Senior Secured Notes In an exciting development, Berry Global Group, Inc. (NYSE:BERY) has outlined plans for the issuance of senior secured notes through its subsidiary, Treasure Escrow Corporation. This move is a crucial step in conjunction with the anticipated merger of Berry's Health, Hygiene and Specialties Global Nonwovens and...

Continue Reading
Hexaware Technologies Expands Presence with New London HQ

Updated Category News Views 260

Hexaware Technologies Expands Its Footprint with New Headquarters Hexaware Technologies, a renowned name in the realm of IT, AI, and digital services, has recently taken a significant step by inaugurating its new UK headquarters at One Canada Square, in the vibrant Canary Wharf area. This new facility is set to play a crucial role in the company’s strategy to enhance...

Continue Reading
Aroa Biosurgery Advances in Treating Venous Leg Ulcers

Updated Category News Views 343

Aroa Biosurgery Advances in Treating Venous Leg Ulcers Aroa Biosurgery, a leading name in soft tissue regeneration technology, has achieved a significant milestone in clinical evidence for their proprietary Endoform product. The company announced that over 100 peer-reviewed studies now confirm the efficacy of their AROA ECM technology in treating various wound types....

Continue Reading
Innovative Paver Spacer Designed for Perfect Alignment

Updated Category News Views 231

Revolutionizing Landscape Design with a New Paver Spacer The landscape industry is continuously evolving, and one of the most exciting innovations to recently emerge is a specialized paver spacer. This unique design addresses a common problem faced by landscapers and homeowners alike: the challenge of aligning concrete or clay pavers effectively. An inventor with a vision...

Continue Reading
Transforming Diagnostics: The Rise of Digital Pathology Market

Updated Category News Views 232

Understanding Digital Pathology Market Dynamics In recent years, the Digital Pathology Market has emerged as a key player in the healthcare sector, showing significant growth and innovation. With an expected market size of USD 2.92 billion by the end of the forecast period, the sector has captured investor interest and demonstrated the potential to reshape diagnostic...

Continue Reading